Anti-neutrophil antibodies in primary sclerosing cholangitis

Best Practice and Research: Clinical Gastroenterology

Volumn 15, Issue 4, 2001, Pages 629-642

  Terjung, Birgit ^a,b   Worman, Howard J ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

ANCA; Autoantibodies; Autoimmune liver disorders; Autoimmunity; Primary sclerosing cholangitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; MITOCHONDRION ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; SMOOTH MUSCLE ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; RAT;

EID: 0034879311     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2001.0209     Document Type: Article

References (100)

1. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
2. Autoantibodies against neutrophils and monocytes: Tools for diagnosis and marker of disease activity in Wegener's granulomatosis
3. Anticytoplasmic antibodies in Wegener's granulomatosis
4. Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis
5. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
6. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis
7. Anticytoplasmic antibodies: Their immunodiagnostic value in Wegener granulomatosis
8. Antineutrophil antibodies in vasculitis
9. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease
10. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases
11. Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis
12. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis
13. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis
14. Antineutrophil cytoplasmic antibodies in autoimmune liver diseases
15. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases
16. High-titer antineutrophil cytoplasmic antibodies in type I autoimmune hepatitis
17. Antineutrophil cytoplasmic antibodies in autoimmune hepatitis
18. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis
19. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA
20. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA)
21. Antineutrophil cytoplasmic and other autoantibodies in primary sclerosing cholangitis
22. Antineutrophil cytoplasmatic antibodies and their diagnostic significance as serum markers
23. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease
24. ANCA and associated diseases: Immunodiagnostic and pathogenetic aspects
25. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease
26. Autoimmune reactivity in inflammatory bowel disease
27. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins
28. 'Atypical p-ANCA' in IBD and hepatobiliary disorders react with a 50 kD nuclear envelope protein of neutrophils and myeloid cell lines
29. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies
30. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: Non-histone chromosomal proteins, HMGI and HMG2
31. High mobility group (HMG) non-histone chromosomal proteins HMGI and HMG2 are significant target antigens of perinuclear antineutrophil cytoplasmic antibodies in autoimmune hepatitis
32. Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis
33. Identification of histone HI as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA
34. Interphase nuclei of many mammalian cell types contain deep, dynamic, tubular membrane-bound invaginations of the nuclear envelope
35. Target antigens for anti-neutrophil cytoplasmic antibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils
36. Formalin fixation and patterns of antineutrophil cytoplasmic antibodies
37. Demonstration of circulating antinuclear globulins in ulcerative colitis
38. Granulocyte specific antinuclear antibodies in ulcerative colitis
39. Antineutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis
40. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis
41. Antineutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role
42. Neutrophil antibodies (pANCA) in chronic liver disease and inflammatory bowel disease: Do they react with different antigens?
43. Antineutrophil nuclear antibodies (ANNA) in primary biliary cirrhosis: Their prevalence and antigen specificity
44. Prevalence and clinical significance of anti-lactoferrin autoantibodies in inflammatory bowel diseases and primary sclerosing cholangitis
45. Significance and specificity of antibodies to neutrophils detected by Western blotting for the serological diagnosis of primary sclerosing cholangitis
46. Primary sclerosing cholangitis in 32 children: Clinical, laboratory, and radiographic features, with survival analysis
47. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: Prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease
48. Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium
49. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique
50. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: A comparison of the alkaline phosphatase and immunofluorescent techniques
51. Wegener's autoantigen decoded
52. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis
53. Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis
54. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis
55. Circulating autoantibodies directed against beta-glucuronidase
56. Antigen specificities and clinical distribution of ANCA in kidney diseases
57. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: The lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane glomerular endothelial cells
58. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and medical and surgical treatment
59. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: Defined specificities may be associated with distinct clinical features
60. Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-I
61. Identification and characterization of autoantibodies against catalase and α-enolase in patients with primary sclerosing cholangitis
62. Catalase and α-enolase: Two novel granulocyte antigens in inflammatory bowel disease (IBD)
63. Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiologic potential
64. Clinical and pathological classification of ANCA-associated vasculitis: What are the controversies?
65. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides
66. The Glomerular Disease Collaborative Network: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis
67. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients
68. A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: Relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment
69. Anti-neutrophil cytoplasmic antibody: A prognostic indicator in primary sclerosing cholangitis
70. Neutrophil cytoplasmic autoantibodies after liver transplantation in patients with primary sclerosing cholangitis
71. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to scoring system for the diagnosis of autoimmune hepatitis
72. Autoimmune cholangitis within the spectrum of autoimmune liver disease
73. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody
74. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis
75. Association of primary sclerosing cholangitis with HLA-B8
76. Association of primary sclerosing cholangitis with HLADRw52a
77. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis
78. Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis
79. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo
80. Effect of tumor necrosis factor-induced integrin activation on Fcγ-receptor II-mediated signal transduction: Relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies
81. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): A FcγRII-dependent process
82. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming
83. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies
84. A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation peptide
85. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis
86. Models of antineutrophil cytoplasmic antigen-associated systemic vasculitis and their clinical relevance
87. Factors involved in the pathogenesis of neutrophilic vasculitis in MRL/Mp-Ipr/lpr mice: A model for human microscopic angiitis
88. The search for pathogenic antigens in ulcerative colitis
89. Anti-neutrophil cytoplasmic in a rat model of trinitrobenzenesulphonic acid-induced liver injury
90. A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNT-alpha production and autoantibodies
91. Antineutrophil cytoplasmic antibodies in T cell receptor α-deficient mice with chronic colitis
92. An antibody profile in primary sclerosing cholangitis
93. Primary sclerosing cholangitis in the presence of a lupus anticoagulant
94. Case report. Anti-proteinase 3 antibody activity in a patient with primary sclerosing cholangitis: Clinical remission following ursodeoxycholic acid therapy
95. Serum autoantibodies in patients with primary sclerosing cholangitis
96. Autoantibody profile of primary sclerosing cholangitis
97. Elevated circulating immune complexes in primary sclerosing cholangitis
98. Primary sclerosing cholangitis: A review and its clinical features, cholangiography, and hepatic histology
99. Immune disorders of the liver and bile ducts
100. Clinicopathologic features of the syndrome of primary sclerosing cholangitis